Intravenous golimumab in rheumatoid arthritis.
Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.
Mayo Clinic, 668 Humboldt St, Denver, CO 80218, USA.
Marc D
MD
Cohen
Edward C
EC
Keystone
D061605:Administration, Intravenous; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; C529000:golimumab
TNF-α inhibition; anti-TNF-α antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF-α inhibition